In Reply We thank Messori and Clark et al for their letters. Messori asked us to comment on whether treatment-related adverse events cost more for repackaged (compounded) bevacizumab, which does not have regulatory approval for intravitreous use. He emphasized that the medicolegal aspects of treatment-related adverse events have become increasingly expensive from a malpractice perspective, and he is concerned about isolated clusters of endophthalmitis events that were due to errors in repackaging.
Neil M. Bressler, Adam R. Glassman, David W. Hutton. Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema—Reply. JAMA Ophthalmol. 2017;135(3):291–292. doi:10.1001/jamaophthalmol.2016.5686